Antimicrobial resistance is no longer an emerging issue. It is a structural reality reshaping the foundations of modern medicine. The effectiveness of antibiotics—one of the defining achievements of the twentieth century—is steadily eroding under the evolutionary pressure of bacteria. The paradox is becoming increasingly clear: as medicine advances technologically, its ability to control infections is, in some cases, weakening.
Beyond the logic of broad-spectrum medicine
For decades, the pharmaceutical model has relied on broad-spectrum solutions designed to target a wide range of pathogens. Antibiotics are the most powerful expression of this approach. Bacteriophages operate differently. Their strength lies in specificity, adaptability, and a dynamic interaction with their biological target. They do not act indiscriminately. They identify, attack, and replicate with precision.
A biological response to resistance
This specificity makes bacteriophages particularly relevant in the context of antimicrobial resistance. Where antibiotics lose effectiveness, phages can be selected—or engineered—to bypass resistance mechanisms. Their evolutionary nature enables continuous adaptation, creating a biological “arms race” that evolves alongside bacterial threats, without relying solely on the development of new chemical compounds.
The limits of existing regulatory models
This same adaptability, however, challenges the foundations of pharmaceutical development. Phage therapy does not easily fit within existing regulatory frameworks. It is not inherently standardized. Treatments may require personalization, matching specific phages to specific bacterial strains, with tailored production and characterization processes. This raises critical questions about validation, quality, safety, and reproducibility.
From product to system thinking
The challenge is not only regulatory, but conceptual. How do you evaluate a therapy that evolves? How do you integrate it into development pipelines designed for stable, well-defined products? Regulatory bodies and scientific communities are beginning to explore more flexible approaches, capable of accommodating this complexity while maintaining rigorous standards.
Industrial implications and emerging models
At the same time, industrial interest is accelerating. Startups, biotech companies, and research centers are developing new platforms, manufacturing models, and clinical strategies. The goal is not simply to produce phages, but to build systems capable of managing variability, customization, and scalability.
A shift toward ecosystem-based medicine
Bacteriophages do more than expand the therapeutic toolbox. They challenge the underlying logic of anti-infective treatment. The shift is from static to dynamic, from a finished product to a living system interacting continuously with both patient and pathogen. It is a transition from a product-based model to an ecosystem-based approach.
The beginning of a new trajectory
This is where the real transformation lies. Not only in demonstrating clinical efficacy—already observed in several contexts—but in integrating this approach into healthcare systems built on different assumptions. Bacteriophages represent not an immediate universal solution, but a strategic direction. One that forces the industry to rethink established models and opens the path toward a new era of therapeutic innovation.
For a deeper exploration of bacteriophages in the fight against antimicrobial resistance, including regulatory and industrial implications, read the full article published by EIPG.
